title: Remarkable progress toward new treatments for cystic fibrosis.
authors.affiliation: Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA, USA.
authors.forename: Laurie C
authors.initials: LC
authors.lastname: Eldredge
authors.affiliation: Department of Pediatrics, Seattle Children's Research Institute, University of Washington, Seattle, WA 98121, USA. Electronic address: bonnie.ramsey@seattlechildrens.org.
authors.forename: Bonnie W
authors.initials: BW
authors.lastname: Ramsey
mesh_terms: D000627:Aminophenols / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D000818:Animals; D052117:Benzodioxoles / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003550:Cystic Fibrosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D004195:Disease Models, Animal; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D009154:Mutation / Q000235:genetics; D015363:Quinolones / Q000627:therapeutic use
chemical_list: D000627:Aminophenols; D000631:Aminopyridines; D052117:Benzodioxoles; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor; C569105:lumacaftor